| 39.11 0 (0%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 47.83 | 1-year : | 51.02 |
| Resists | First : | 40.95 | Second : | 43.68 |
| Pivot price | 39.32 |
|||
| Supports | First : | 36.52 | Second : | 30.39 |
| MAs | MA(5) : | 40.81  |
MA(20) : | 39.37 |
| MA(100) : | 39.32 |
MA(250) : | 39.24 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 52.8 |
D(3) : | 71.3 |
| RSI | RSI(14): 47.8 | |||
| 52-week | High : | 50.84 | Low : | 26.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ESTA ] has closed above bottom band by 46.7%. Bollinger Bands are 16.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.18 - 39.37 | 39.37 - 39.57 |
| Low: | 36.93 - 37.12 | 37.12 - 37.32 |
| Close: | 38.79 - 39.11 | 39.11 - 39.43 |
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Thu, 25 Sep 2025
Establishment Labs Holdings Inc. $ESTA Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Mon, 22 Sep 2025
Goldman Sachs Group Inc. Cuts Position in Establishment Labs Holdings Inc. $ESTA - MarketBeat
Wed, 17 Sep 2025
Establishment Labs appoints Peter Caldini as CEO - MSN
Wed, 13 Aug 2025
Lewin Nicholas Sheridan buys Establishment Labs (ESTA) shares worth $78,879 - Investing.com
Thu, 07 Aug 2025
Establishment Labs Reports Second Quarter 2025 Financial Results - Business Wire
Thu, 07 Aug 2025
ESTABLISHMENT LABS HOLDINGS INC. SEC 10-Q Report - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 29 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 104.7 (%) |
| Shares Short | 5,120 (K) |
| Shares Short P.Month | 4,760 (K) |
| EPS | -3.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.79 |
| Profit Margin | -49.9 % |
| Operating Margin | -27.5 % |
| Return on Assets (ttm) | -12.8 % |
| Return on Equity (ttm) | -261.2 % |
| Qtrly Rev. Growth | 16.2 % |
| Gross Profit (p.s.) | 4.11 |
| Sales Per Share | 6.12 |
| EBITDA (p.s.) | -1.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -73 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -12.7 |
| PEG Ratio | 0 |
| Price to Book value | 49.5 |
| Price to Sales | 6.38 |
| Price to Cash Flow | -15.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|